靶向肿瘤及其微环境：间充质干细胞介导的基因靶向治疗策略(英文) 被引量：1

Aiming at tumors and their microenvironments: Targeted strategies of mesenchymal stem cell-mediated genetic therapy

导出

摘要恶性肿瘤的早期诊断以及特异性药物的应用,已证实可以延长众多恶性肿瘤患者的中位生存期。然而,由于许多药物的药代动力学欠佳,在全身给药时常迅速失活,甚至无法到达肿瘤灶。基于对肿瘤组织的趋向性,基因修饰的间充质干细胞提供了一种颇具潜力的投送药物的细胞载体。随着恶性肿瘤的快速进展,肿瘤的间质微环境被激活并进一步促进肿瘤进展。因此,同时靶向肿瘤细胞及其微环境的新型肿瘤治疗策略可能为恶性肿瘤的治疗提供新的机遇。 The early detection of some cancer types combined with the advent of specific drugs has increased median survival of numerous cancer patients. However, many drugs with poor pharmacokinetics rapidly lose activity when delivered systemically and may even not reach the tumors. Based on tropism for tumors, genetic-modified mesenchymal stem cells provide a promising cellular vehicle for drug deliveries. During rapid progression of cancer disease, an activated stromal microenvironment is produced to facilitate tumor development. As a result, it appears a potential chance to modify the cancer therapy in a way, aiming at both the tumor cells and their microenvironments.

作者曲戈马军秦建军

机构地区郑州大学河南省肿瘤医院胸外科郑州大学第二附属医院消化病研究所

出处《肿瘤》 CAS CSCD 北大核心 2013年第5期465-472,共8页 Tumor

基金国家自然科学基金资助项目(编号:81071909)

关键词肿瘤间充质干细胞肿瘤微环境基因治疗 Neoplasms Mesenchymal stem cells Tumor microenvironment Genetic therapy

分类号 R730.54 [医药卫生—肿瘤]

引文网络
相关文献

参考文献32

1DOMINICI M, LE BLANC K, MUELLER I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement[J]. Cytotherapy, 2006, 8(4):315-317.
2GRISENDI G, BUSSOLARI R, CAFARELLI L, et al. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy[J]. Cancer Res, 2010, 70(9):3718-3729.
3ZISCHEK C, NIESS H, ISCHENKO I, et al. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma[J]. Ann Surg, 2009, 250(5):747-753.
4ZOU W, ZHENG H, HE T C, by mesenchymal stem et al, LIGHT delivery to tumors cells mobilizes an effective antitumor immune response[J]. Cancer Res, 2012 72(12):2980-2989.
5KIDD S, CALDWELL L, DIETRICH M, et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment[J]. Cytotherapy, 2010, 12(5):615-625.
6FIERRO F, KALOMOIRIS S, SONDERGAARD C, et al. Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy[J]. Stem Cells, 2011,29(11):1727-1737.
7LE BLANC K. FRASSONI F stem cells for treatment BALL L, et al. of steroid-res Mesenchyma stant, severe acute graft-versus-host disease: a phase II study[J] Lancet, 2008, 371 (9624):1579-1586.
8DAI L J, MONIRI M R, ZENG Z R, et al. Potential implications of mesenchymal stem cells in cancer therapy[J]. Cancer Lett, 2011, 305(1):8-20.
9MOMIN E N, VELA G, ZAIDI H A, et al. The oncogenic potential of mesenchymal stem cells in the treatment of cancer: directions for future research[J]. Curr Immunol Rev, 2010, 6(2):137-148.
10CHENG Z. OU L. ZHOU mesenchymal stem ce X, et al. Targeted migration of s modified with CXCR4 gene to infarcted myocardium improves cardiac performance[J] Mol Ther, 2008, 16(3):571-579.